p53 Function and Dysfunction in Human Health and Diseases
Conflicts of Interest
References
- Kastenhuber, E.R.; Lowe, S.W. Putting p53 in Context. Cell 2017, 170, 1062–1078. [Google Scholar] [CrossRef] [Green Version]
- Muller, P.A.; Vousden, K.H. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell 2014, 25, 304–317. [Google Scholar] [CrossRef] [Green Version]
- Sabapathy, K.; Lane, D. Therapeutic targeting of p53: All mutants are equal, but some mutants are more equal than others. Nat. Rev. Clin. Oncol. 2018, 15, 13–30. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Carlsen, L.; Hernandez Borrero, L.; Seyhan, A.A.; Tian, X.; El-Deiry, W.S. Advanced strategies for therapeutic targeting of wild-type and mutant p53 in cancer. Biomolecules 2022, 12, 548. [Google Scholar] [CrossRef] [PubMed]
- Schulz-Heddergott, R.; Moll, U.M. Gain-of-function (GOF) mutant p53 are actionable therapeutic target. Cancers 2018, 10, 188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Puca, R.; Nardinocchi, L.; Porru, M.; Simon, A.S.; Rechavi, G.; Leonetti, C.; Givol, D.; D’Orazi, G. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 2011, 10, 1679–1689. [Google Scholar] [CrossRef]
- Yu, X.; Vazquez, A.; Levine, A.J.; Carpizo, D.R. Allele-Specific p53 Mutant Reactivation. Cancer Cell 2012, 21, 614–625. [Google Scholar] [CrossRef] [Green Version]
- Cirone, M.; Garufi, A.; Di Renzo, L.; Franato, M.; Faggioni, A.; D’Orazi, G. Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells. Oncoimmunology 2013, 2, e26198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vakifahmetoglu-Norberg, H.; Kim, M.; Xia, H.-G.; Iwanicki, M.P.; Ofengeim, D.; Coloff, J.; Pan, L.; Ince, T.A.; Kroemer, G.; Brugge, J.S.; et al. Chaperone-mediated autophagy degrades mutant p53. Genes Dev. 2013, 27, 1718–1730. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rodriguez, O.C.; Choudhury, S.; Kolukula, V.; Vietsch, E.E.; Catania, J.; Preet, A.; Reynoso, K.; Bargnetti, J.; Wellstein, A.; Albanese, C.; et al. Dietary downregulation of mutant p53 levels via glucose restriction: Mechanisms and implications for tumor therapy. Cell Cycle 2012, 11, 4436–4446. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garufi, A.; Pucci, D.; D’Orazi, V.; Cirone, M.; Bossi, G.; Avantaggiti, M.L.; D’Orazi, G. Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis. 2014, 5, e1271. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Romeo, M.A.; Gilardini Montani, M.S.; Benedetti, R.; Arena, A.; D’Orazi, G.; Cirone, M. p53-R273H sustains ROS, pro-inflammatory cytokines release and mTOR activation while reducing autophagy, mitophagy and UCP2 expression, effects prevented by wtp53. Biomolecules 2021, 11, 344. [Google Scholar] [CrossRef]
- Wallis, B.; Bowman, K.R.; Lu, P.; Lim, C.S. The challenges and prospects of p53-based therapies in ovarian cancer. Biomolecules 2023, 13, 159. [Google Scholar] [CrossRef]
- Da Silva, P.F.F.; Mota Goveia, R.; Bomfim Teixeira, T.; Faulin Gamba, B.; de Lima, A.P.; Rogatto, S.R.; de Paula Silvera-Lacerda, E. TP53 pathogenic variants in early-onset breast cancer patients fulfilling hereditary breast and ovarian cancers and Li-Fraumeni-like syndromes. Biomolecules 2022, 12, 640. [Google Scholar] [CrossRef]
- Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387, 296–299. [Google Scholar] [CrossRef] [PubMed]
- Henningsen, K.M.; Manzini, V.; Magerhans, A.; Gerber, S.; Dobbelstein, M. MDM2-driven ubiquitination rapidly removes p53 from its cognate promoters. Biomolecules. 2021, 12, 22. [Google Scholar] [CrossRef]
- Jung, J.H.; Lee, D.; Ko, H.M.; Jang, H.-J. Inhibition of CNOT2 induces apoptosis via MID1IP1 in colorectal cancer cells by activating p53. Biomolecules 2021, 11, 1492. [Google Scholar] [CrossRef] [PubMed]
- Lundsten, S.; Berglund, H.; Jha, P.; Krona, C.; Hariri, M.; Nelander, S.; Lane, D.P.; Nestor, M. p53-mediated radiosensitization of 177Lu-DOTATATE in neuroblastoma tumor spheroids. Biomolecules 2021, 11, 1695. [Google Scholar] [CrossRef] [PubMed]
- Middei, S.; Giorgini, L.; Vacca, V.; Storri, F.; Putti, S.; Strimpakos, G.; Raspa, M.; Scavizzi, F.; Moretti, F.; D’Amato, F.R. Early social enrichment modulates tumor progression and p53 expression in adult mice. Biomolecules 2022, 12, 532. [Google Scholar] [CrossRef] [PubMed]
- Sivaraman, L.; Conneely, O.M.; Medina, D.; O’Malley, B.W. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc. Natl. Acad. Sci. USA 2001, 98, 12379–12384. [Google Scholar] [CrossRef] [Green Version]
- Cirone, M.; D’Orazi, G. NRF2 in cancer: Croos-talk with oncogenic pathways and involvement in gamma herpesviruses-driven carcinogenesis. Int. J. Mol. Sci. 2023, 24, 595. [Google Scholar] [CrossRef]
- Garufi, A.; Pistritto, G.; D’Orazi, V.; Cirone, M.; D’Orazi, G. The impact of NRF2 inhibition on drug-induced colon cancer cell death and p53 activity: A pilot study. Biomolecules 2022, 12, 461. [Google Scholar] [CrossRef]
- D’Orazi, G.; Cirone, M. Mutant p53 and cellular stress pathways: A criminal alliance that promotes cancer progression. Cancers 2019, 11, 614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xiao, Q.; Werner, J.; Venkatachalam, N.; Boonekamp, K.E.; Ebert, M.P.; Zhan, T. Cross-talk between p53 and Wnt signaling in cancer. Biomolecules 2022, 12, 453. [Google Scholar] [CrossRef] [PubMed]
- Butera, G.; Manfredi, M.; Fiore, A.; Brandi, J.; Pacchiana, R.; De Giorgis, V.; Barberis, E.; Vanella, V.; Galasso, M.; Scupoli, M.T.; et al. Tumor suppressor role of wild-type p53-dependent secretome and its proteomic identification in PDAC. Biomolecules 2022, 12, 305. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
D’Orazi, G. p53 Function and Dysfunction in Human Health and Diseases. Biomolecules 2023, 13, 506. https://doi.org/10.3390/biom13030506
D’Orazi G. p53 Function and Dysfunction in Human Health and Diseases. Biomolecules. 2023; 13(3):506. https://doi.org/10.3390/biom13030506
Chicago/Turabian StyleD’Orazi, Gabriella. 2023. "p53 Function and Dysfunction in Human Health and Diseases" Biomolecules 13, no. 3: 506. https://doi.org/10.3390/biom13030506